NCT02471859

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	GDC-3280	GDC-3280 at various doses, depending on the cohort and treatment period
DRUG	Placebo	Placebo at various doses, depending on the cohort and treatment period

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2015-06-15
• Last updated: 2016-03-17

Locations

1 site across 1 country: United Kingdom